The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes

References

• Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor b (PDGFRB) gene in BCR–ABL-negative chronic myeloproliferative disorders. Br J Haematol. 2003; 120: 251–256.
   PubMed Web of Science ®Google Scholar
• Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481–487.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014; 123: 3574–3577.
   PubMed Web of Science ®Google Scholar
• David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2007; 109: 61–66.
   PubMed Web of Science ®Google Scholar
• Ross DM, Altamura HK, Hahn CN, et al. Delayed diagnosis leading to accelerated phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. Leukemia. 2016;30:1402–1405.
   PubMed Web of Science ®Google Scholar
• Praga M, Sevillano A, Auñón P, et al. Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant. 2015; 30:1472–1479.
   PubMed Web of Science ®Google Scholar
• Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant.2004; 19:2778–2783.
   PubMed Web of Science ®Google Scholar
• Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. l989;35:1257–1270.
   PubMed Web of Science ®Google Scholar
• Adrianto I, Wang S, Wiley GB, et al. Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum. 2012;64: 3695–3705.
   PubMed Web of Science ®Google Scholar
• Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015; 90:1077–1089.
   PubMed Web of Science ®Google Scholar
• Erben P, Gosenca D, Müller MC, et al. Screening for diverse PDGFRA and PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica. 2010; 95:738–744.
   PubMed Web of Science ®Google Scholar
• Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003; 102: 4187–4190.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Curtis C, Apperley JF, Stark A, et al. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. Br J Haematol. 2010; 148: 268–273.
   PubMed Web of Science ®Google Scholar
• Rosati R, La Starza R, Luciano L, et al. TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukemia. 2006; 20:1623–1624.
   PubMed Web of Science ®Google Scholar
• Walz C, Metzgeroth G, Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica. 2007; 92: 163–169.
   PubMed Web of Science ®Google Scholar
• Gallagher G, Horsman DE, Tsang P et al. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Cancer Genet Cytogenet. 2008; 181: 46–51.
   PubMedGoogle Scholar
• Naumann N, Schwaab J, Metzgeroth G, et al. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Genes Chromosomes Cancer. 2015; 54: 762–770.
   PubMed Web of Science ®Google Scholar
• Winkelmann N, Hidalgo-Curtis C, Waghorn K, et al. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. Leuk Lymphoma. 2013; 54:1527–1531.
   PubMed Web of Science ®Google Scholar
• Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood.1998; 91:4419–4426.
   PubMed Web of Science ®Google Scholar
• Medves S, Noël LA, Montano-Almendras CP, et al. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica. 2011;96: 1406–1414.
   PubMed Web of Science ®Google Scholar
• Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood.2001; 97:3910–3918.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Heath C, Parker S, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 2000;60: 3592–3598.
   PubMed Web of Science ®Google Scholar
• Golub TR, Barker GF, Lovett M, et al. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994; 77: 307–316.
   PubMed Web of Science ®Google Scholar
• Cornfield D, Shah U, Cross N, et al. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib. J Clin Oncol. 2012;30:109–111.
   Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Sternberg DW, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005;19:27–30.
   PubMed Web of Science ®Google Scholar
• Gong SL, Guo MQ, Tang GS, et al. Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature. Oncol lett. 2016;11:770–774.
   PubMed Web of Science ®Google Scholar
• Vizmanos JL, Novo FJ, Román JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res. 2004;64:2673–2676.
   PubMed Web of Science ®Google Scholar
• La Starza R, Rosati R, Roti G, et al. A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome. Leukemia. 2007;21:830–833.
   PubMed Web of Science ®Google Scholar
• Gosenca D, Kellert B, Metzgeroth G, et al. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Genes Chromosomes Cancer 2014;53:411–421.
   PubMed Web of Science ®Google Scholar
• Grand FH, Burgstaller S, Kühr T, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 2004; 64: 7216–7219.
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 2001; 98:2518–2525.
   PubMed Web of Science ®Google Scholar
• Walz C, Haferlach C, Hänel A, et al. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer 2009; 48:179–183.
   PubMed Web of Science ®Google Scholar
• Morerio C, Acquila M, Rosanda C, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004; 64: 2649–2651.
   PubMed Web of Science ®Google Scholar
• Provenzano JD, Kuebler JP. Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy. Case Rep Hematol. 2013;2013:709164.
   PubMedGoogle Scholar
• Bell GC, Padron E, et al. Detection of a PDGFRB fusion in refractory CMML without eosinophilia: a case for broad spectrum tumor profiling. Leuk Res Rep. 2015; 4:70–71.
   PubMedGoogle Scholar